Navigation Links
BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Date:11/19/2013

BETHLEHEM, Pa., Nov. 19, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), has been contracted by BHR Pharma to develop an in-field nasally applied formulation of Progesterone for traumatic brain injury (TBI).  BHR is pioneering this treatment and is well into their study, SyNAPSe® (Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries), a global, Phase 3, multi-center pivotal trial in severe TBI using a parenteral formulation that was independently developed.  According to Mark Mitchnick, MD, Particle Sciences' CEO, "Particle Sciences focuses on formulation design and manufacturing.  Our clients often face challenging delivery issues so the dosage forms we work with frequently require a high level of engineering and the simplification of complex formulation challenges to commercially viable products.  In this case, the challenge was achieving rapid onset under conditions of true duress, trauma.  The product had to be versatile and durable.  BHR are world leaders in this therapeutic approach and working with their technical team we have been able to design a dosage form that meets their needs.  We look forward to helping BHR bring this very important product into the clinic and through to commercialization."        

Particle Sciences is an integrated pharmaceutical CDMO.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and ma
'/>"/>

SOURCE Particle Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Maximizing Production Capacity for Growth - Finding 5% for Pharmaceutical or Biotech Companies through Facility Optimization, a New Life Science Webinar from Xtalks
2. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
3. IPISC announces IP insurance for the Biotechnology/Pharma Industry
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
7. HealthEconomics.Com Distinguished Again as Top Influencer at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress in Dublin
8. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
9. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
10. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
11. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... 2014  NeuroSigma, Inc., a Los Angeles ... technologies, today announced that it has filed a registration ... Exchange Commission relating to a proposed initial public offering ... be offered and the price range for the proposed ... LLC will act as the book-running manager for the ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis ... structures of all Mers CoV virus strains ... structures back to 2012.  This conservation and sharing of ... a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
(Date:8/26/2014)... of engineers from Singapore has successfully piloted the ... satellite communications. , With the weight of payloads ... a lightweight, low power-consuming, wireless communication system to ... always been a challenge for system designers. , ... of Nanyang Technological University in Singapore launched VELOX-I, ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ZigBee in the Sky 2
... move aside. Tiny gold stars, smaller than a billionth ... to medical diagnoses or testing for environmental contaminants. , While ... sciences, a new study by Duke University bioengineers indicates that ... above all the rest for certain applications. , The ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 6 ... developer in the treatment of multiple sclerosis (MS), ... quarter ended,September 30, 2008. BioMS Medical, in partnership ... (MBP8298), a drug for the,treatment of MS undergoing ...
... ... LymphoStat-B(R) Phase 3 trials; first Phase 3 ... in mid-2009 - ... Genome Sciences,Inc. (Nasdaq: HGSI ) today announced financial results and key developments,for the quarter ended September ...
Cached Biology Technology:Gold nanostar shape of the future 2Gold nanostar shape of the future 3BioMS Medical Announces Third Quarter 2008 Results 2BioMS Medical Announces Third Quarter 2008 Results 3BioMS Medical Announces Third Quarter 2008 Results 4BioMS Medical Announces Third Quarter 2008 Results 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10
(Date:8/25/2014)... manipulating the behavior of ants emits a cocktail ... its natural target host, but not when infecting ... findings, which suggest that the fungus "knows" its ... mechanisms underlying this phenomenon, according to researchers., "Fungi ... chemicals that affect their environment," noted lead author ...
(Date:8/25/2014)... as a lightning strike on August 12, 2014. Currently ... There are close to 2,000 personnel working on ... fires and a number of large ones. Most of ... about 100 acres. An inversion layer settled over the ... 24, keeping fire activity moderate. As the inversion lifted in ...
(Date:8/25/2014)... 25, 2014  Scribe Labs unveiled its first ... and saw its campaign surpass the $50,000 funding ... kinematic metrics that help an athlete understand how ... their running mechanics. Built with an advanced 9-axis ... most advanced set of running metrics available outside ...
Breaking Biology News(10 mins):Zombie ant fungi 'know' brains of their hosts 2Zombie ant fungi 'know' brains of their hosts 3Happy Camper and July Fire Complexes in California 2runScribe Fitness Wearable Exceeds 200% of Kickstarter Goal in First Week 2
... by the University of Colorado at Boulder and the ... liquid crystals of ultrashort DNA molecules immersed in water, ... the emergence of life on Earth. CU-Boulder ... surprisingly short segments of DNA, lifes molecular carrier of ...
... quack-quack there. Farmers may find phytochemicals to be the ... in the bucket that cashes in on the tug-o-war ... the Texas Agricultural Experiment Station. Thats because applying ... increases disease-preventing phytochemicals, or nutrients, for which consumers may ...
... in remote parts of the UK, southern Scandinavia and ... dissolved organic matter. In this weeks Nature journal (22 ... (University College London) and the US Environmental Protection Agency ... a return to a more natural, pre-industrial state following ...
Cached Biology News:Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 2Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 3Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 4Old McDonald had a phytochemical 2Old McDonald had a phytochemical 3Don't judge a brook by its color -- brown waters are more natural 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: